Humacyte (HUMA) Other Non-Current Liabilities (2020 - 2026)

Humacyte (HUMA) has reported Other Non-Current Liabilities for 7 consecutive years, with $15.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 41.38% year-over-year to $15.7 million in Q2 2026; TTM through Jun 2026 was $15.7 million, a 41.38% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, down 72.67% from the prior year.
• Other Non-Current Liabilities was $15.7 million for Q2 2026 at Humacyte, up from $10.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $100.4 million in Q1 2022 and troughed at $10.8 million in Q1 2026.
• A 5-year average of $41.6 million and a median of $39.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 8010.09% in 2022, down 73.09% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $27.9 million in 2022, then soared by 35.93% to $37.9 million in 2023, then surged by 87.15% to $71.0 million in 2024, then slumped by 72.67% to $19.4 million in 2025, then decreased by 19.29% to $15.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $15.7 million (Q2 2026), $10.8 million (Q1 2026), and $19.4 million (Q4 2025), per Business Quant data.